OTCMCHGCY
Market cap69bUSD
Dec 20, Last price
21.34USD
1D
0.05%
1Q
-10.90%
Name
Chugai Pharmaceutical Co Ltd
Chart & Performance
Profile
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 1,111,367,000 -11.79% | 1,259,946,000 26.02% | 999,759,000 27.04% | |||||||
Cost of revenue | 700,754,000 | 726,637,000 | 577,862,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 410,613,000 | 533,309,000 | 421,897,000 | |||||||
NOPBT Margin | 36.95% | 42.33% | 42.20% | |||||||
Operating Taxes | 118,349,000 | 156,737,000 | 116,390,000 | |||||||
Tax Rate | 28.82% | 29.39% | 27.59% | |||||||
NOPAT | 292,264,000 | 376,572,000 | 305,507,000 | |||||||
Net income | 325,472,000 -13.08% | 374,429,000 23.58% | 302,995,000 41.10% | |||||||
Dividends | (131,594,000) | (138,220,000) | (98,644,000) | |||||||
Dividend yield | 1.50% | 2.49% | 1.61% | |||||||
Proceeds from repurchase of equity | 212,000 | 236,000 | 314,000 | |||||||
BB yield | 0.00% | 0.00% | -0.01% | |||||||
Debt | ||||||||||
Debt current | 6,434,000 | 6,550,000 | ||||||||
Long-term debt | 6,480,000 | 7,245,000 | 9,000,000 | |||||||
Deferred revenue | 378,000 | 430,000 | 490,000 | |||||||
Other long-term liabilities | 12,585,000 | 14,555,000 | 15,641,000 | |||||||
Net debt | (733,756,000) | (210,327,000) | (254,596,000) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 409,925,000 | 244,112,000 | 279,626,000 | |||||||
CAPEX | (71,948,000) | (71,239,000) | (72,866,000) | |||||||
Cash from investing activities | (37,290,000) | (145,994,000) | (118,927,000) | |||||||
Cash from financing activities | (139,331,000) | (145,641,000) | (107,408,000) | |||||||
FCF | 294,323,000 | 196,713,000 | 206,936,000 | |||||||
Balance | ||||||||||
Cash | 738,982,000 | 503,107,000 | 471,970,000 | |||||||
Long term investments | 1,254,000 | (279,101,000) | (201,824,000) | |||||||
Excess cash | 684,667,650 | 161,008,700 | 220,158,050 | |||||||
Stockholders' equity | 1,556,225,000 | 1,355,582,000 | 1,119,795,000 | |||||||
Invested Capital | 953,875,350 | 1,185,824,300 | 903,737,950 | |||||||
ROIC | 27.32% | 36.04% | 36.77% | |||||||
ROCE | 24.97% | 39.39% | 37.29% | |||||||
EV | ||||||||||
Common stock shares outstanding | 1,645,499 | 1,645,338 | 1,645,229 | |||||||
Price | 5,342.00 58.61% | 3,368.00 -9.83% | 3,735.00 -32.13% | |||||||
Market cap | 8,790,255,567 58.63% | 5,541,498,155 -9.82% | 6,144,931,185 -32.12% | |||||||
EV | 8,056,499,567 | 5,331,171,155 | 5,890,335,185 | |||||||
EBITDA | 442,353,000 | 564,743,000 | 452,765,000 | |||||||
EV/EBITDA | 18.21 | 9.44 | 13.01 | |||||||
Interest | 61,000 | 48,000 | ||||||||
Interest/NOPBT | 0.01% | 0.01% |